Major Depressive Disorder

Looking to stay up to date on MDD research? This research collection reviews outcomes on metabolic abnormalities, biomarkers, and more.

Test your knowledge on issues in major depressive disorder.

First of its kind culturally sensitive adherence scale factors in CVD risk factors to find ways to best support patients.

“Our hope for patients suffering from TRD is that their serious, but often treatable condition is recognized earlier in the treatment paradigm, and they are put on a treatment that works best for their specific type of depression.”

What is the current role of lithium?

From gut microbiota and SSRIs in MDD to nonpharmacological interventions following TBI, here are highlights from the week in Psychiatric Times.

A gut feeling? Researchers analyzed the gut microbiome in major depression disorder and its modulation by SSRI antidepressants.

New results for a study evaluating lumateperone.

Study results show that the therapy activates serotonin (5-HT) and improves stress-coping ability.

The Future of Mental Health: Ketamine Therapy Report revealed that 55% of Americans who tried at home ketamine took more than the recommended dose.

Transcranial direct current stimulation for depression.

Sleep and suicide: researchers performed a systematic review and meta-analysis of objective sleep markers of suicidal behaviors in patients with psychiatric disorders.

Researchers analyzed data from the National Survey of Religious Leaders on the state of the psychiatrist-clergy alliance.

Here are 9 things you need to know about the clinical management of major depressive disorder.

Fatigue is a very common physical complaint. What therapeutic options are available?

"The history of medicine is rich in blaming the disease or the patient for 'untreatable' symptoms, until we stumble upon or develop a treatment that is, in fact, effective."

From special issues in diagnosing and treating catatonia to helping justice-involved individuals re-enter the community, here are highlights from the week in Psychiatric Times.

SPL026 with supportive therapy sees positive results in patients with major depressive disorder.

Catatonia: learn more about how to best diagnose early.

Is inflammation a biomarker of antidepressant efficacy? Researchers analyzed blood CRP levels as a predictor of response to antidepressants.

There may not be a diagnosis for ‘New Year Depression,’ about 10% to 20% of individuals in the US may get a milder form of these winter blues.

Metabolic depression? Researchers performed a metabolomic evaluation of patients with treatment-resistant depression.

From current treatments for cannabis use disorder to new possibilities for the treatment of dementia, here are highlights from the week in Psychiatric Times.

Charles Montano, MD; Carmen Kosicek, MSN, PMHNP-BC; and Gus Alva, MD, DFAPA, review the impact of the duration of MDD episodes and goals of managing episode recurrences.

Cariprazine is now FDA-approved as an adjunctive therapy to antidepressants.

From an in-depth analysis of ADHD in clinical practice to differences in effectiveness between intravenous and intranasal ketamine, here are highlights from the week in Psychiatric Times.

This latest submission completes the FDA filing that was initiated in May.

Does route of administration affect antidepressant efficacy of ketamine? Researchers performed a meta-analysis of trials comparing intravenous and intranasal administration.

Here’s why most of the claims recently made about antidepressants in Newsweek are wrong.